Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.69 |
| ▸ | MLYCD | O95822 | 2/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4329157 | 0.92 | MAPK14 (0.80) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4335579 | 0.90 | MAPK14 (0.70) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4335445 | 0.90 | MAPK14 (0.70) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL10091871 | 0.89 | MAPK14 (0.69) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL27891827 | 0.89 | MAPK14 (0.57) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4335420 | 0.87 | MAPK14 (0.75) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4334599 | 0.87 | MAPK14 (0.65) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4339559 | 0.85 | MAPK14 (0.67) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4332754 | 0.83 | MAPK14 (0.61) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4341536 | 0.83 | MAPK14 (0.63) | MAPK14MLYCDMAPK9MAPK10MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11576914-B2 | Drug for treating or preventing disorder caused by TGF-β signaling, and application thereof | THE DOSHISHA (JP) | 2023-02-14 | — | — | US | disclosed |
| US-20210008067-A1 | DRUG FOR TREATING OR PREVENTING DISORDER CAUSED BY TGF-ß SIGNALLING, AND APPLICATION THEREOF | THE DOSHISHA (JP) | 2021-01-14 | — | — | US | disclosed |
| EP-3659626-A1 | DRUG FOR TREATING OR PREVENTING DISORDER CAUSED BY TGF- SIGNALLING, AND APPLICATION THEREOF | The Doshisha (JP) | 2020-06-03 | — | — | EP | disclosed |
| US-8207203-B2 | Pyridylisoxazole derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | MAPK14 43/4885MLYCD 4475/4885MAPK9 35/4885 |
| US-11576914-B2 | Drug for treating or preventing disorder caused by TGF-β signaling, and application thereof | TGFBR1, FIBP, TGFB1 | MAPK14 133/4885MLYCD 4583/4885MAPK9 61/4885 |
| US-20210008067-A1 | DRUG FOR TREATING OR PREVENTING DISORDER CAUSED BY TGF-ß SIGNALLING, AND APPLICATION THEREOF | TGFBR1, TGFB1, FIBP | MAPK14 120/4885MLYCD 4591/4885MAPK9 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.